lifestyle.side.cr

Author: Knight Therapeutics

Notice of Knight Therapeutics’ Fourth Quarter and Year End 2025 Results Conference Call

March 12, 2026
Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil

February 18, 2026